IN2014DN05972A - - Google Patents

Info

Publication number
IN2014DN05972A
IN2014DN05972A IN5972DEN2014A IN2014DN05972A IN 2014DN05972 A IN2014DN05972 A IN 2014DN05972A IN 5972DEN2014 A IN5972DEN2014 A IN 5972DEN2014A IN 2014DN05972 A IN2014DN05972 A IN 2014DN05972A
Authority
IN
India
Prior art keywords
diseases associated
present
glucose metabolism
therapeutic agent
abnormal glucose
Prior art date
Application number
Other languages
English (en)
Inventor
Ichiro Hisatome
Shunsuke Tsujimoto
Takashi Shirakura
Shinya Hiramitsu
Original Assignee
Teijin Pharma Ltd
Nat Univ Corp Tottori Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Nat Univ Corp Tottori Univ filed Critical Teijin Pharma Ltd
Publication of IN2014DN05972A publication Critical patent/IN2014DN05972A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN5972DEN2014 2012-01-27 2013-01-25 IN2014DN05972A (enrdf_load_html_response)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012015351 2012-01-27
PCT/JP2013/051627 WO2013111870A1 (ja) 2012-01-27 2013-01-25 糖尿病の治療薬

Publications (1)

Publication Number Publication Date
IN2014DN05972A true IN2014DN05972A (enrdf_load_html_response) 2015-06-26

Family

ID=48873581

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5972DEN2014 IN2014DN05972A (enrdf_load_html_response) 2012-01-27 2013-01-25

Country Status (15)

Country Link
US (1) US20150005506A1 (enrdf_load_html_response)
EP (1) EP2808018B1 (enrdf_load_html_response)
JP (1) JP5924699B2 (enrdf_load_html_response)
KR (1) KR20140134266A (enrdf_load_html_response)
CN (1) CN104066430A (enrdf_load_html_response)
AR (1) AR089812A1 (enrdf_load_html_response)
AU (1) AU2013212865A1 (enrdf_load_html_response)
BR (1) BR112014017902A2 (enrdf_load_html_response)
CA (1) CA2862602A1 (enrdf_load_html_response)
HK (1) HK1201209A1 (enrdf_load_html_response)
IN (1) IN2014DN05972A (enrdf_load_html_response)
MX (1) MX2014008484A (enrdf_load_html_response)
RU (1) RU2014134845A (enrdf_load_html_response)
TW (1) TW201334779A (enrdf_load_html_response)
WO (1) WO2013111870A1 (enrdf_load_html_response)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104610188B (zh) * 2015-02-10 2016-07-27 佛山市赛维斯医药科技有限公司 含苯基脒结构的腈基苯噻唑羧酸酰胺类化合物、其制备及用途
CN104610190B (zh) * 2015-02-10 2016-08-17 佛山市赛维斯医药科技有限公司 一类含环丙基脒结构的卤代苯基噻唑羧酸酰胺类化合物及用途
CN104628671B (zh) * 2015-02-10 2016-04-13 佛山市赛维斯医药科技有限公司 含苯基脒结构的硝基苯噻唑羧酸酰胺类化合物及用途
CN104628672A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含苯基脒结构的烷氧苯基噻唑羧酸酰胺类化合物及用途
CN104628673A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含叔丁基脒结构的腈基苯噻唑羧酸酰胺类化合物及用途
KR102473677B1 (ko) * 2015-08-17 2022-12-02 삼성디스플레이 주식회사 액정 표시 장치
JP6732004B2 (ja) 2016-02-19 2020-07-29 国立大学法人鳥取大学 認知症治療薬または予防薬

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009279A1 (en) * 1990-11-30 1992-06-11 Teijin Limited 2-arylthiazole derivative and pharmaceutical composition containing the same
HUP9902721A2 (hu) * 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
US20050074442A1 (en) * 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
EP1778261A4 (en) * 2004-07-21 2010-08-11 Univ Florida COMPOSITIONS AND METHODS FOR TREATMENT AND DIAGNOSIS OF INSULIN RESISTANCE
WO2007018687A1 (en) * 2005-07-21 2007-02-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of hyperuricemia related health consequences
WO2007019153A2 (en) 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
CA2630639A1 (en) * 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
JP2007210978A (ja) * 2006-02-13 2007-08-23 Hiroshima Univ 耐糖能障害、ｉｉ型糖尿病、高脂血症、メタボリックシンドローム、内臓脂肪型肥満、脂肪肝または非アルコール性脂肪性肝炎の予防・治療剤
US20080269226A1 (en) 2006-11-13 2008-10-30 Christopher Lademacher Methods for Preserving Renal Function Using Xanthine Oxidoreductase Inhibitors
CN102643241B (zh) * 2007-11-27 2015-01-21 亚德生化公司 化合物和组合物以及使用方法
PL2266989T3 (pl) * 2008-03-31 2016-04-29 C&C Res Lab Pochodne heterocykliczne
KR101613611B1 (ko) * 2008-04-30 2016-04-19 웰스태트 테러퓨틱스 코포레이션 요산 감소용 테트라졸 화합물
EP2291189B1 (en) * 2008-05-22 2014-10-01 AstraZeneca AB Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
EP2398319A4 (en) * 2008-10-19 2012-11-14 Richard J Johnson THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CHRONIC NEPHITIA ASSOCIATED WITH METABOLIC IMBALANCE
US20120219536A1 (en) * 2009-08-24 2012-08-30 Queensland University Of Technology Purine-targeted diagnosis and therapy of wounds
KR101872189B1 (ko) * 2010-06-16 2018-06-29 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타제 억제제 또는 크산틴 옥시다제 억제제의 신규한 조절 방출 제형
PE20130241A1 (es) * 2010-06-25 2013-03-04 Teijin Pharma Ltd Agente terapeutico de liberacion sostenida para la hipertension y la disfuncion renal

Also Published As

Publication number Publication date
US20150005506A1 (en) 2015-01-01
RU2014134845A (ru) 2016-03-20
JP5924699B2 (ja) 2016-05-25
EP2808018B1 (en) 2018-03-14
TW201334779A (zh) 2013-09-01
CN104066430A (zh) 2014-09-24
HK1201209A1 (en) 2015-08-28
KR20140134266A (ko) 2014-11-21
EP2808018A4 (en) 2015-07-15
AU2013212865A1 (en) 2014-08-14
CA2862602A1 (en) 2013-08-01
AR089812A1 (es) 2014-09-17
JPWO2013111870A1 (ja) 2015-05-11
BR112014017902A2 (pt) 2017-08-22
WO2013111870A1 (ja) 2013-08-01
EP2808018A1 (en) 2014-12-03
MX2014008484A (es) 2014-10-14

Similar Documents

Publication Publication Date Title
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
IN2015MN00404A (enrdf_load_html_response)
AU2012214029A8 (en) Rorgammat inhibitors
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12017501426A1 (en) Derivatives of betulin
PH12015502839B1 (en) Antiviral compounds
MY183312A (en) Pharmaceutical formulation
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
MX2015005286A (es) Procedimiento para la preparación de derivados del ácido biliar.
IN2015DN00185A (enrdf_load_html_response)
MX2015010971A (es) Derivado novedoso de pirazol.
JO3530B1 (ar) مركبات بيريدازين 1،4-ثنائية الإرتباط ونظائرها وطرق معالجة نقص smn وحالاته المرضية.
IN2014MN02106A (enrdf_load_html_response)
IN2014DN05972A (enrdf_load_html_response)
AU2012321815A8 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
MY187718A (en) Pharmaceutical formulations
MX390763B (es) Compuestos de tetraciclina
PH12015501752A1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
MX2021010046A (es) Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.
WO2011123536A8 (en) Polycyclic tetracycline compounds
WO2011159124A3 (ko) Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
NZ711343A (en) Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
IN2014CN04449A (enrdf_load_html_response)
MY173491A (en) Therapeutic or prophylactic agent for biliary tract diseases
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids